8-K: Akoya Biosciences Completes Merger with Quanterix Subsidiary, Becomes Wholly-Owned Entity

Akoya Biosciences, Inc. has completed its merger with Wellfleet Merger Sub, Inc., a wholly-owned subsidiary of Quanterix Corporation, resulting in Akoya becoming a wholly-owned subsidiary of Quanterix.

Summary

• The merger of Akoya Biosciences, Inc. (Akoya) with Wellfleet Merger Sub, Inc. (Merger Sub), a wholly-owned subsidiary of Quanterix Corporation (Quanterix), was completed on July 8, 2025.
• Akoya survived the merger as a wholly-owned subsidiary of Quanterix.
• Each share of Akoya common stock outstanding immediately prior to the merger was converted into the right to receive 0.1461 of a fully paid and nonassessable share of Quanterix common stock and $0.38 in cash.
• The Per Share Stock Consideration and Per Share Cash Consideration are subject to adjustment to ensure the aggregate number of Quanterix shares issued does not exceed 19.99% of its outstanding shares immediately prior to the merger, and the aggregate cash consideration does not exceed $20,000,000.
• Unvested Akoya Restricted Stock Units (RSUs) were converted into restricted stock units with respect to Per Share Merger Consideration, retaining their original terms and vesting conditions, with certain vesting accelerations applied.
• Vested Akoya RSUs were cancelled in consideration for the right to receive the Per Share Merger Consideration.
• Akoya Options with an exercise price equal to or greater than the implied value of the Per Share Merger Consideration were terminated and cancelled for no consideration.
• Akoya Options with an exercise price less than the implied value of the Per Share Merger Consideration were terminated and cancelled for the right to receive Per Share Merger Consideration based on a synthetic cashless exercise.
• Akoya repaid all outstanding obligations and terminated its Credit and Security Agreement, dated October 27, 2020.
• Akoya terminated its 2021 Employee Stock Purchase Plan.
• Akoya provided notice of termination of its Equity Distribution Agreement, dated November 7, 2022, with Piper Sandler & Co.
• Akoya requested that the Nasdaq Stock Market LLC suspend trading of Akoya Common Stock and will file Form 25 to delist and terminate its Section 12(b) registration.
• Akoya intends to file Form 15 to terminate its Section 15(d) reporting obligations.
• A change in control of Akoya occurred, making it a wholly-owned subsidiary of Quanterix.
• Akoya's Certificate of Incorporation was amended and restated, and the bylaws of Merger Sub became the Amended and Restated Bylaws of Akoya.

Sentiment

Score: 7

Explanation: The document reports the successful completion of a pre-announced merger, which is a positive for the parties involved as it signifies the execution of a strategic transaction. While it marks the end of Akoya as an independent public entity, the terms of the merger were previously disclosed and the completion is an expected outcome. The repayment of debt and termination of certain agreements are also positive administrative closures.

Positives

• Akoya's Credit and Security Agreement, dated October 27, 2020, was fully repaid and terminated, eliminating associated debt obligations.
• The merger provides Akoya shareholders with a combination of Quanterix stock and cash, offering both liquidity and continued equity participation in the combined entity.

Negatives

• Akoya's common stock will be delisted from the Nasdaq Global Select Market, and its registration under the Exchange Act will be terminated, ending its independent public trading status.
• Akoya's 2021 Employee Stock Purchase Plan was terminated, which may impact employee benefits.
• Akoya's Equity Distribution Agreement with Piper Sandler & Co. was terminated, ending its ability to raise capital through that specific facility.

Risks

• The Per Share Stock Consideration and Per Share Cash Consideration are subject to adjustment, which could result in a lower value for Akoya shareholders if the aggregate number of Quanterix shares issued exceeds 19.99% of its outstanding shares or the aggregate cash consideration exceeds $20,000,000.
• Akoya Options with an exercise price equal to or greater than the implied value of the Per Share Merger Consideration were terminated for no consideration, meaning holders of these options received no value.

Future Outlook

Akoya Biosciences, Inc. will cease to be an independent publicly traded company and will operate as a wholly-owned subsidiary of Quanterix Corporation, with its common stock delisted from Nasdaq and its SEC reporting obligations terminated.

Industry Context

This merger represents consolidation within the biotechnology and life sciences sector, specifically in areas related to advanced diagnostics or research tools. Quanterix specializes in ultra-sensitive protein detection, while Akoya focuses on spatial biology. Such mergers often aim to combine complementary technologies, expand market reach, and achieve operational synergies within the industry.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders (Akoya): Received consideration in Quanterix stock and cash, losing their direct equity in Akoya and its independent public trading status.
• Employees (Akoya): The 2021 Employee Stock Purchase Plan was terminated, and executive officers changed, potentially impacting compensation and leadership. Employees with RSUs and Options had their awards converted or cancelled based on the merger terms.
• Creditors (Akoya): The Credit and Security Agreement was repaid, indicating a positive resolution of debt obligations.
• Quanterix: Gained a wholly-owned subsidiary, expanding its business and potentially creating synergies.

Next Steps

• Akoya will file with the SEC a Notification of Removal from Listing and/or Registration on Form 25 to withdraw its common stock from Nasdaq and terminate its Section 12(b) registration.
• Akoya intends to file with the SEC a certification and notice of termination on Form 15 to terminate its Section 15(d) reporting obligations.

Key Dates

Recommendation

Keywords

Akoya Biosciences, Quanterix Corporation, Merger, Acquisition, SEC Filing, 8-K, Delisting, Stock Consideration, Cash Consideration, Corporate Governance, Biotechnology, Life Sciences, Diagnostics